World Health Assembly 67: HAI intervention on the WHO's framework of engagement with non-state actors

A new (and improved) model to regulate pharmaceutical promotion

Enhancing accountability in the medicines market: The Medicines Transparency Alliance


Statement on Medicines Patent Pool

DG Trade State of Play reveals EU's ambitions for IP protection in FTAs

Conflicts of Interest and the Future of Financing for WHO.

DG Trade public hearing on the “Protection and enforcement of IPR in third countries

Foundations: Conlicts of interests and Democracy issues

Corporate funding linked to EU patient & consumer groups policy


EMA reviews transparency criteria

HAI research on financial disclosure featured in article: European politicians' call for greater transparency

HAI Europe Statement: EMA talks the ‘conflicts of interest’ talk, but will it walk the walk?

In perspective: EMA comments on HAI Europe's survey of financial disclosure

Impact of HAI Europe survey results: Two weeks on

HAI Europe survey reveals new data on financial transparency of patient and consumer organisations

Open Health Forum: more room for civil society?

Priorities of the Belgian Presidency

HAI Europe recommendations for improved conflict of interest declarations at EMA

ISDB & MiEF criticize EMA over conflict of interest procedures

Citizens call for inquiry into EU response to H1N1 outbreak

European Medicines Agency faces tough questions about patient groups' transparency

HAI hosts essay competition for students

Patient Groups need dose of transparency

Roundtable on ACTA by TACD

Generic prescribing policies 1 – ABPI 0

Snooping CEO unveils conflicts of interest at the European Medicines Agency

No NGO briefings will be allowed during World Health Assembly this year.

HAI Response: ACTA Stakeholders Meeting in European Parliament